Although the administration of combined therapy is efficient to tuberculosis (TB) treatment caused by susceptible Mycobacterium tuberculosis strains, to overcome the multidrug resistance is still a challenge. Some studies have reported evidence about tetrahydropyridines as a putative efflux pump inhibitor, including in mycobacteria, being a promising strategy against M. tuberculosis. Thus, we investigated the biological potential of 2,2,2-trifluoro-1-(1,4,5,6-tetrahydropyridin-3-yl)ethanone derivative (NUNL02) against two strains of M. tuberculosis. NUNL02 was able to increase the susceptibility of the multidrug resistant strain to the anti-TB drugs, resulting in synergism with rifampicin. Still, we assume that this compound plays a role in the efflux mechanism in M. tuberculosis, besides, to be able to kill the bacillus under the deprivation of essential nutrients. Thus, our findings highlight NUNL02 as a promising prototype to develop a new adjuvant for TB treatment, mainly as EPI.

尽管联合治疗对易感结核分枝杆菌菌株引起的结核病（TB）治疗有效，但克服多重耐药性仍然是一个挑战。一些研究报告了关于四氢吡啶作为推定的外排泵抑制剂的证据，包括在分枝杆菌中，是一种有希望的抗结核分枝杆菌策略。因此，我们研究了 2,2,2-trifluoro-1-(1,4,5,6-tetrahydropyridin-3-yl)ethanone 衍生物 (NUNL02) 对两种结核分枝杆菌菌株的生物学潜力. NUNL02 能够增加多重耐药菌株对抗结核药物的敏感性，从而与利福平产生协同作用。尽管如此，我们仍然假设这种化合物在结核分枝杆菌的外排机制中发挥作用，此外，能够在缺乏必需营养素的情况下杀死芽孢杆菌。因此，我们的研究结果突出了 NUNL02 作为开发新的结核病治疗佐剂（主要作为 EPI）的有前途的原型。